News
VIRI
0.4509
-0.24%
-0.0011
Weekly Report: what happened at VIRI last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at VIRI last week (0401-0405)?
Weekly Report · 04/08 11:57
Weekly Report: what happened at VIRI last week (0325-0329)?
Weekly Report · 04/01 11:54
12 Health Care Stocks Moving In Monday's Pre-Market Session
Landos Biopharma (NASDAQ:LABP) shares moved upwards by 181.6% to $22.05 during Monday's pre-market session. Altamira Therapeutics shares rose 49.71% after their Q4 earnings report came out yesterday. Neuronetics stock increased by 18.19% in pre- market.
Benzinga · 03/25 13:05
Weekly Report: what happened at VIRI last week (0318-0322)?
Weekly Report · 03/25 11:58
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Cannabis legalization, drug approval, a delisting update and more are the biggest pre-market stock movers on Monday morning. Next e GO stock is rocketing more than 127% alongside heavy pre- market trading this morning. Salarius Pharmaceuticals shares are surging over 28% following cannabis legalization in Germany. The top 10 biggest losers include a company undergoing a reverse stock split.
Investorplace · 03/25 11:36
12 Health Care Stocks Moving In Friday's Intraday Session
IMAC Hldgs (NASDAQ:BACK) shares moved upwards by 91.5% to $2.47 during Friday's regular session. The company's Q4 earnings report came out yesterday. Virios Therapeutics shares increased by 37.98% and Ontrak shares rose by 35.03% in the same session.
Benzinga · 03/22 17:31
12 Health Care Stocks Moving In Thursday's Pre-Market Session
10 Bioscience (NASDAQ:YTEN) stock increased by 133.7% to $0.57 during Thursday's pre-market session. The company's market cap is at $5.2 billion. Immunovant and argenx stock moved upwards by 14.0% and 13.24% respectively. Losers Tourmaline Bio and Avinger stock decreased by 33.4% during the pre- market session.
Benzinga · 03/21 13:05
Weekly Report: what happened at VIRI last week (0311-0315)?
Weekly Report · 03/18 11:56
Weekly Report: what happened at VIRI last week (0304-0308)?
Weekly Report · 03/11 11:51
Virios Therapeutics: A Hold Rating with a New Price Target Amidst Clinical and Financial Challenges
H.C. Wainwright analyst Sean Lee CFA maintained a Hold rating on Virios Therapeutics and set a price target of $0.40. The company is advancing its IMC-2 program for the treatment of long-COVID. The potential market for LC treatments is substantial.
TipRanks · 03/06 11:38
Weekly Report: what happened at VIRI last week (0226-0301)?
Weekly Report · 03/04 11:55
Virios Therapeutics reports Q4 results
Seeking Alpha · 03/01 15:49
Virios Therapeutics Q4 2023 GAAP EPS $(0.06) Beats $(0.09) Estimate
Benzinga · 02/29 14:17
*Virios Therapeutics: Discussions Ongoing With Potential Partners to Fund Advancement of IMC-1 Into Phase 3 Development for FM >VIRI
Dow Jones · 02/29 14:16
BRIEF-Virios Therapeutics Q4 EPS USD -0.06
Reuters · 02/29 14:15
Press Release: Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
Virios Therapeutics announces financial results for the fourth quarter and full year ended December 31, 2023. The company is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases. Virios has reached alignment with FDA on using fatigue response as the primary end point to evaluate IMC-2 for Long-COVID.
Dow Jones · 02/29 14:15
Virios Therapeutics Inc: Statement of changes in beneficial ownership of securities
Press release · 02/28 18:07
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress And Key Upcoming Milestones; All Of Virios' Employees Have Agreed To A 10% Salary Compensation Reduction In Exchange For Future Vesting Stock Options
Virios Therapeutics, Inc. Is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases. The company will hold a special shareholder meeting on March 1, 2024. Virios is seeking approval to execute a reverse stock split in 2024. The Company has agreed to a 10% salary cut.
Benzinga · 02/28 14:21
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
Virios Therapeutics, Inc. Is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases. Shareholder Letter highlights the Company's progress and key milestones in 2024. The company is focused on fibromyalgia and long-coVID.
Barchart · 02/28 08:15
More
Webull provides a variety of real-time VIRI stock news. You can receive the latest news about Virios Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VIRI
Virios Therapeutics, Inc. is a development-stage biotechnology company. The Company is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. IMC-2 is a combination of valacyclovir and celecoxib that is believed to have specific activity against Epstein-Barr virus (herpesvirus HHV-4), as well as other herpesviruses. IMC-1 and IMC-2 combine two specific mechanisms of action purposely designed to inhibit herpesvirus activation and replication, thereby converting activated herpesvirus back to dormancy and/or by keeping the herpesvirus in a latent or dormant state.